Genes within risk loci were prioritized following the general approach previously described41. Genes were given prioritization scores based on the weighted sum of evidence across all evidence categories: FUMA positional, eQTL, and CI mapping, variant and gene annotation scores (CADD, predicted loss of impact [pLI], and RDB scores), positional overlap in fine-mapping, significance in gene-based analyses, brain tissue TWAS, eQTL SMR, and pQTL SMR. Weights for each evidence category are provided in Supplementary Table 31. Within a given locus, the evidence scores were compared across genes to identify the most likely causal gene. Genes with scores ≥ 4 were ranked as either Tier 1 (greater likelihood of being the causal risk gene) or Tier 2 (lower likelihood of being the causal risk gene) and genes with scores < 4 were left unranked. The ranking algorithm is as follows. For a given locus, if there was a gene whose evidence score ≥ 4 and this gene’s score was > 20% higher than all other genes in the locus, it was ranked as a Tier 1 gene (greater likelihood of being the
